HAVEN 2 Updated Analysis: Multicentre, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Paediatric Patients with Haemophilia A with Inhibitors

被引：0
|
作者：
Young, G. [1 ]
Sidonio, R. F. [2 ,3 ]
Liesner, R. [4 ]
Oldenburg, J. [5 ]
Chang, T. [6 ]
Uguen, M. [7 ]
Dhalluin, C. [7 ]
Schmitt, C. [7 ]
Levy, G. G. [6 ]
Shima, M. [8 ]
Mahlangu, J. [9 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Great Ormond St Hosp Sick Children, London, England
[5] Univ Klinikum Bonn, Bonn, Germany
[6] Genentech Inc, San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Nara Med Univ Hosp, Kashihara, Nara, Japan
[9] Univ Witwatersrand, Johannesburg, South Africa
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
emicizumab; haemophilia A; inhibitors; paediatric;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-OR-0
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [1] HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors
    Young, Guy
    Sidonio, Robert F.
    Liesner, Ri
    Oldenburg, Johannes
    Chang, Tiffany
    Uguen, Marianne
    Dhalluin, Christophe
    Schmitt, Christophe
    Levy, Gallia G.
    Shima, Midori
    Mahlangu, Johnny
    BLOOD, 2017, 130
  • [2] Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
    Pipe, Steven W.
    Shima, Midori
    Lehle, Michaela
    Shapiro, Amy
    Chebon, Sammy
    Fukutake, Katsuyuki
    Key, Nigel S.
    Portron, Agnes
    Schmitt, Christophe
    Podolak-Dawidziak, Maria
    Bienz, Nives Selak
    Hermans, Cedric
    Campinha-Bacote, Avrita
    Kiialainen, Anna
    Peerlinck, Kathelijne
    Levy, Gallia G.
    Jimenez-Yuste, Victor
    LANCET HAEMATOLOGY, 2019, 6 (06): : E295 - E305
  • [3] Surgical Experience in Two Multicentre, Open-label Phase 3 Studies of Emicizumab in Persons with Haemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)
    Kruse-Jarres, R.
    Callaghan, M.
    Croteau, S. E.
    Jimenez-Yuste, V.
    Khoo, L.
    Liesner, R.
    Matsushita, T.
    Recht, M.
    Young, G.
    Chang, T.
    Dhalluin, C.
    Mu, Y.
    Xu, J.
    Devenport, J.
    Ko, R.
    Solari, P.
    Oldenburg, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 128 - 128
  • [4] Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
    Negrier, Claude
    Mahlangu, Johnny
    Lehle, Michaela
    Chowdary, Pratima
    Catalani, Olivier
    Bernardi, Ronald J.
    Jimenez-Yuste, Victor
    Beckermann, Benjamin M.
    Schmitt, Christophe
    Ventriglia, Giuliana
    Windyga, Jerzy
    d'Oiron, Roseline
    Moorehead, Paul
    Koparkar, Sunita
    Teodoro, Vanda
    Shapiro, Amy D.
    Oldenburg, Johannes
    Hermans, Cedric
    LANCET HAEMATOLOGY, 2023, 10 (03): : e168 - e177
  • [5] Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
    Young, Guy
    Srivastava, Alok
    Kavakli, Kaan
    Ross, Cecil
    Sathar, Jameela
    You, Chur-Woo
    Tran, Huyen
    Sun, Jing
    Wu, Runhui
    Poloskey, Stacey
    Qiu, Zhiying
    Kichou, Salim
    Andersson, Shauna
    Mei, Baisong
    Rangarajan, Savita
    LANCET, 2023, 401 (10386): : 1427 - 1437
  • [6] A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
    Escobar, Miguel
    Dunn, Amy
    Quon, Doris
    Trzaskoma, Ben
    Lee, Lucy
    Ko, Richard H.
    Carpenter, Shannon L.
    HAEMOPHILIA, 2022, 28 (04) : E105 - E108
  • [7] A multicentre open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in paediatric patients with moderately to severely active ulcerative colitis
    Turner, D.
    Veereman, G.
    Hyams, J.
    Griffiths, A.
    Chan, D.
    Adedokun, O. J.
    Damaraju, L.
    Strauss, R.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S364 - S365
  • [8] A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    Young, Guy
    Liesner, Ri
    Chang, Tiffany
    Sidonio, Robert, Jr.
    Oldenburg, Johannes
    Jimenez-Yuste, Victor
    Mahlangu, Johnny
    Kruse-Jarres, Rebecca
    Wang, Michael
    Uguen, Marianne
    Doral, Michelle Y.
    Wright, Lilyan Y.
    Schmitt, Christophe
    Levy, Gallia G.
    Shima, Midori
    Mancuso, Maria Elisa
    BLOOD, 2019, 134 (24) : 2127 - 2138
  • [9] Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
    Tiede, Andreas
    Hart, Christina
    Knoebl, Paul
    Greil, Richard
    Oldenburg, Johannes
    Sachs, Ulrich J.
    Miesbach, Wolfgang
    Pfrepper, Christian
    Trautmann-Grill, Karolin
    Holstein, Katharina
    Pilch, Jan
    Moehnle, Patrick
    Schindler, Christoph
    Weigt, Carmen
    Schipp, Dorothea
    May, Marcus
    Dobbelstein, Christiane
    Pelzer, Fabius J.
    Werwitzke, Sonja
    Klamroth, Robert
    LANCET HAEMATOLOGY, 2023, 10 (11): : E913 - E921
  • [10] Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Haemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicentre, Open-label, Phase 3 Study (HAVEN 4)
    Jimenez-Yuste, V.
    Shima, M.
    Fukutake, K.
    Lehle, M.
    Chebon, S.
    Retout, S.
    Portron, A.
    Levy, G. G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 135 - 135
12345